B Cell Bosses

Gut bacteria in mice spur regulatory B cells to differentiate and release an anti-inflammatory cytokine.

Written byKate Yandell
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

MICROBIAL INSTIGATORS: Conventionally housed mice are exposed to ample amounts of bacteria, which colonize their guts. When researchers induce arthritis in the mice by injecting them with foreign antigens, the animals’ macrophages and dendritic cells go into overdrive, producing the cytokines IL-1β and IL-6 (1). These cytokines lead to acute arthritis (2). But they also drive the development of Bregs, which produce the anti-inflammatory cytokine IL-10 that subsequently quells arthritic symptoms (3). Meanwhile, mice raised in a sterile environment or given antibiotics to knock down their gut microbiota (4) suffer less acute arthritis, due to a relative lack of IL-1β, IL-6, and other pro-inflammatory cytokines. They also produce fewer Bregs (5). © KIMBERLY BATTISTA

The paper
E.C. Rosser et al., “Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production,” Nat Med, 20:1334-39, 2014.

Elizabeth Rosser was partway through her PhD at University College London when her experiments stopped working. Using a mouse model of arthritis, she was trying to understand how invariant natural killer T cells—white blood cells that help guide the body’s response to inflammation—interact with regulatory B cells (Bregs), which put a damper on inflammatory responses. But when the university’s Centre for Rheumatology moved to a new building, experimental mice didn’t get arthritis—and also didn’t develop Bregs.

It is well-known that animals’ immune systems do not always behave the same way in new, very clean housing facilities as in older ones. The literature shows ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies